Oxford Immunotec Global PLC (OXFD) Trading Up 5.4%
Oxford Immunotec Global PLC (NASDAQ:OXFD) was up 5.4% during trading on Monday . The stock traded as high as $10.07 and last traded at $9.80, with a volume of 93,424 shares trading hands. The stock had previously closed at $9.30.
Several equities research analysts recently commented on OXFD shares. BTIG Research restated a “buy” rating and set a $17.00 target price on shares of Oxford Immunotec Global PLC in a research report on Monday, June 27th. Zacks Investment Research lowered Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. Finally, Piper Jaffray Cos. restated a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Sunday, June 26th.
The firm’s market cap is $217.79 million. The company’s 50 day moving average is $8.92 and its 200 day moving average is $9.67.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $19.20 million for the quarter, compared to analysts’ expectations of $18.10 million. The firm’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.33) EPS. Equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.29) earnings per share for the current year.
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.